Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen Snags Another Approval for This Promising Cancer Drug
Amgen Snags Another Approval for This Promising Cancer Drug
Amgen Snags Another Approval for This Promising Cancer Drug
Submitted by
admin
on February 16, 2022 - 10:48am
Source:
Motley Fool
News Tags:
Amgen
Japan
Lumakras
non-small cell lung cancer
advanced non-small cell lung cancer
Headline:
Amgen Snags Another Approval for This Promising Cancer Drug
snippet:
Amgen now has access to nearly 5,000 potential patients in Japan.
This indication should create nearly $200 million in annual revenue for Amgen.
The pharma stock offers investors a market-beating 3.3% dividend yield.
Do Not Allow Advertisers to Use My Personal information
